Secondary Progressive Multiple Sclerosis Drug Market
Secondary Progressive Multiple Sclerosis Drug Market Size, Share & Trends Analysis Report By Type (Inebilizumab, GLX-1112, DC-TAB, Etomoxir, IB-MS, and Others), By Application (Hospital, Clinic, and Others) Forecast Period, (2026-2035)
Industry Overview
Secondary progressive multiple sclerosis drug market valued at $4,650.3 million in 2025 and is projected to reach $7,382.1 million by 2035, growing at a CAGR of 4.8% during the forecast period (2026-2035). The global secondary progressive multiple sclerosis drug market is evolving steadily as healthcare systems shift focus toward therapies that address long-term disability progression rather than solely relapse control. SPMS, which typically develops from relapsing-remitting MS (RRMS), represents a significant treatment challenge due to its progressive neurodegenerative component. Market expansion is being supported by rising global MS prevalence, improved diagnostic capabilities, and increasing awareness of the unmet needs in non-relapsing SPMS populations.
Market Dynamics
Rising Transition from RRMS to SPMS Driving Long-Term Therapy Demand
Most individuals initially diagnosed with relapsing-remitting MS eventually transition into SPMS over time, contributing to sustained demand for progression-focused therapies. With over 2.8 million people globally living with MS, the potential SPMS treatment population continues to expand. As disease-modifying therapies (DMTs) improve early survival and relapse control, more patients live long enough to enter the progressive phase, reinforcing long-term market growth.
Advancements in Targeted Immunotherapy and Oral DMTs
The therapeutic landscape has evolved beyond traditional injectables toward oral agents and monoclonal antibodies targeting specific immune pathways. Approved therapies such as siponimod (Mayzent), ofatumumab (Kesimpta), and ublituximab (Briumvi) are indicated for relapsing and active secondary-progressive forms of MS. These agents aim to reduce relapse frequency while slowing disability progression, improving convenience and patient adherence.
Market Segmentation
- Based on the type, the market is segmented into inebilizumab, GLX-1112, DC-TAB, etomoxir, IB-MS, and others.
- Based on the application, the market is segmented into hospital, clinic, and others.
Inebilizumab Segment to Hold a Prominent Market Share
Based on type, the inebilizumab segment is anticipated to account for a significant share of the global secondary progressive multiple sclerosis (SPMS) drug market. The growing focus on targeted biologic therapies that modulate specific immune pathways has positioned monoclonal antibodies such as inebilizumab as promising treatment options. With increasing clinical research activity and rising demand for therapies capable of slowing disability progression, biologics are gaining strong traction in the SPMS landscape. Their potential to address underlying B-cell–mediated mechanisms, combined with expanding regulatory approvals and physician familiarity with monoclonal antibody treatments, is reinforcing this segment’s growth trajectory. As innovation in immunotherapy continues, inebilizumab and similar advanced therapies are expected to remain central to market expansion.
Hospitals Segment to Lead by Application
Based on application, the hospital segment is projected to dominate the global SPMS drug market, driven by the need for specialized neurological care, advanced diagnostic capabilities, and supervised administration of complex therapies. Many SPMS treatments, particularly biologics and investigational therapies, require intravenous infusion, close monitoring, and multidisciplinary management—services primarily delivered in hospital settings. Hospitals also serve as key centers for clinical trials and early adoption of newly approved therapies, further strengthening their market share. While clinics contribute to ongoing patient management and follow-up care, hospitals remain the primary point of care for initiating and managing advanced SPMS treatment regimens, supporting their leading position in this segment.
Regional Outlook
The global secondary progressive multiple sclerosis drug market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Dominates the Market with Established Treatment Infrastructure
North America maintains a leading position in the SPMS drug market due to strong reimbursement frameworks, early regulatory approvals, and high adoption of advanced biologics. Several FDA-approved therapies including siponimod, ofatumumab, and ublituximab are commercially available in the region. The U.S. regulatory system has accelerated development through Breakthrough Therapy designations and priority reviews, particularly for progressive MS therapies. In addition, continuous clinical pipeline activity, including next-generation immunomodulators and neuroprotective agents, strengthens regional leadership. Robust clinical trial participation and active patient advocacy communities further support innovation uptake.
Europe Strengthens Focus on Progressive MS Innovation
Europe is witnessing steady expansion in SPMS therapeutics, supported by strong neurology research networks and early adoption of disease-modifying therapies. European regulators have historically been among the first to approve SPMS-targeted therapies such as siponimod for active disease. Cross-border collaborations and AI-driven research initiatives are also reshaping understanding of MS subtypes, potentially influencing future personalized treatment strategies. Continued regulatory reviews of BTK inhibitors and other next-generation agents are expected to enhance therapeutic options across progressive MS populations.
Market Players Outlook
The major companies operating in the global secondary progressive multiple sclerosis drug market include Biogen Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In December 2024, the FDA granted Breakthrough Therapy designation to Sanofi’s tolebrutinib for non-relapsing secondary-progressive MS, accelerating its development timeline
- In December 2025, Lupin received tentative FDA approval for a generic version of siponimod (Mayzent) for relapsing forms of MS, including active SPMS, signaling the beginning of pricing competition in this segment.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global secondary progressive multiple sclerosis drug Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Secondary Progressive Multiple Sclerosis Drug Market Sales Analysis – Type | Application ($ Million)
- Secondary Progressive Multiple Sclerosis Drug Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Secondary Progressive Multiple Sclerosis Drug Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Secondary Progressive Multiple Sclerosis Drug Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Secondary Progressive Multiple Sclerosis Drug Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Secondary Progressive Multiple Sclerosis Drug Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Secondary Progressive Multiple Sclerosis Drug Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Secondary Progressive Multiple Sclerosis Drug Market Revenue and Share by Manufacturers
- Secondary Progressive Multiple Sclerosis Drug Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Biogen Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Hoffmann-La Roche Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Sanofi S.A.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Teva Pharmaceutical Industries Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Biogen Inc.
- Key Company Analysis
- Global Secondary Progressive Multiple Sclerosis Drug Market Sales Analysis by Type ($ Million)
- Inebilizumab
- GLX-1112
- DC-TAB
- Etomoxir
- IB-MS
- Others
- Global Secondary Progressive Multiple Sclerosis Drug Market Sales Analysis by Application ($ Million)
- Hospital
- Clinic
- Others
- Regional Analysis
- North American Secondary Progressive Multiple Sclerosis Drug Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Secondary Progressive Multiple Sclerosis Drug Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Secondary Progressive Multiple Sclerosis Drug Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- AB Science S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Atara Biotherapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer Aktiengesellschaft
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Biogen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol-Myers Squibb Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hoffmann-La Roche Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GeNeuro SA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Horizon Therapeutics plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Immunic, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lupin Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- MedDay Pharmaceuticals S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck KGaA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Mitsubishi Tanabe Pharma Corporation
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- TG Therapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- UCB S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Viela Bio, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AB Science S.A.
1. Global Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Type, 2025–2035 ($ Million)
2. Global Inebilizumab Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global GLX-1112 Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global DC-TAB Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Etomoxir Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global IB-MS Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Others Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Application, 2025–2035 ($ Million)
9. Global Secondary Progressive Multiple Sclerosis Drug For Hospital Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Secondary Progressive Multiple Sclerosis Drug For Clinic Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Secondary Progressive Multiple Sclerosis Drug For Others Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
13. North American Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
14. North American Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Type, 2025–2035 ($ Million)
15. North American Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Application, 2025–2035 ($ Million)
16. European Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
17. European Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Type, 2025–2035 ($ Million)
18. European Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Application, 2025–2035 ($ Million)
19. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
20. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Type, 2025–2035 ($ Million)
21. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Application, 2025–2035 ($ Million)
22. Rest of the World Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
23. Rest of the World Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Type, 2025–2035 ($ Million)
24. Rest of the World Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Application, 2025–2035 ($ Million)
1. Global Secondary Progressive Multiple Sclerosis Drug Market Share by Type, 2025 Vs 2035 (%)
2. Global Inebilizumab Secondary Progressive Multiple Sclerosis Drug Market Share by Region, 2025 Vs 2035 (%)
3. Global GLX-1112 Secondary Progressive Multiple Sclerosis Drug Market Share by Region, 2025 Vs 2035 (%)
4. Global DC-TAB Secondary Progressive Multiple Sclerosis Drug Market Share by Region, 2025 Vs 2035 (%)
5. Global Etomoxir Secondary Progressive Multiple Sclerosis Drug Market Share by Region, 2025 Vs 2035 (%)
6. Global IB-MS Secondary Progressive Multiple Sclerosis Drug Market Share by Region, 2025 Vs 2035 (%)
7. Global Others Secondary Progressive Multiple Sclerosis Drug Market Share by Region, 2025 Vs 2035 (%)
8. Global Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Application, 2025 Vs 2035 (%)
9. Global Secondary Progressive Multiple Sclerosis Drug For Hospital Market Share by Region, 2025 Vs 2035 (%)
10. Global Secondary Progressive Multiple Sclerosis Drug For Clinic Market Share by Region, 2025 Vs 2035 (%)
11. Global Secondary Progressive Multiple Sclerosis Drug For Others Market Share by Region, 2025 Vs 2035 (%)
12. Global Secondary Progressive Multiple Sclerosis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
13. US Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
14. Canada Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
15. UK Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
16. France Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
17. Germany Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
18. Italy Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
19. Spain Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
20. Russia Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
21. Rest of Europe Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
22. India Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
23. China Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
24. Japan Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
25. South Korea Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
26. Australia and New Zealand Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
27. ASEAN Economies Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
28. Rest of Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
29. Latin America Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
30. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Secondary Progressive Multiple Sclerosis Drug Market in 2025 is estimated to be around $4,650.3 million.
North America holds the largest share in the Secondary Progressive Multiple Sclerosis Drug Market.
Leading players in the Secondary Progressive Multiple Sclerosis Drug Market include Biogen Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., among others.
The Secondary Progressive Multiple Sclerosis Drug Market is expected to grow at a CAGR of 4.8% from 2026 to 2035.
The Secondary Progressive Multiple Sclerosis Drug Market growth is driven by increasing prevalence of multiple sclerosis and rising development of disease-modifying and targeted therapeutic treatments.
